Aquestive Therapeutics
(NASDAQ) AQST
Aquestive Therapeutics Financials at a Glance
Market Cap
$543.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$50.27M
Net Income (TTM)
-$68.91M
EPS (TTM)
-$0.60
P/E Ratio
-7.18
Dividend
$0.00
Beta (Volatility)
1.28 (Average)
Dividend
$0.00
Beta (Volatility)
1.28 (Average)
Price
$4.32
Volume
1,217,295.653
Open
$4.26
Price
$4.32
Volume
1,217,295.653
Open
$4.26
Previous Close
$4.31
Daily Range
$4.24 - $4.34
52-Week Range
$2.93 - $7.55
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
1.28 (Average)
Price
$4.32
Volume
1,217,295.653
Open
$4.26
Previous Close
$4.31
Daily Range
$4.24 - $4.34
52-Week Range
$2.93 - $7.55
Estimated Earnings Date
Aug 10, 2026
AQST News
AQST: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Aquestive Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
147
CEO
Daniel Barber, MBA
Website
www.aquestive.comHeadquarters
Warren, NJ 07059, US
AQST Financials
Key Financial Metrics (TTM)
Gross Margin
63.45%
Operating Margin
-111.18%
Net Income Margin
-137.08%
Return on Equity
190.87%
Return on Capital
-71.23%
Return on Assets
-48.83%
Earnings Yield
-13.93%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$543.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
125.47M
Volume
1.22M
Avg. Volume
1.75M
Financials (TTM)
Gross Profit
$31.90M
Operating Income
-$55.89M
EBITDA
-$51.63M
Operating Cash Flow
-$43.84M
Capital Expenditure
-$479.00K
Free Cash Flow
-$44.32M
Cash & ST Invst.
$110.73M
Total Debt
$133.58M
Aquestive Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$14.45M
+65.7%
Gross Profit
$10.98M
+116.6%
Gross Margin
75.99%
N/A
Market Cap
$543.27MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$3.83M
N/A
Employees
142
N/A
Net Income
-$8.06M
+64.9%
EBITDA
-$4.00M
+78.4%
Quarterly Fundamentals
Total Cash
$110.73M
+61.3%
Total Debt
$133.58M
+241.3%
Accounts Receivable
$6.87M
-34.2%
Inventory
$8.07M
+12.1%
Long Term Debt
$118.26M
+206.6%
Short Term Debt
$15.32M
+2602.5%
Return on Assets
-48.83%
N/A
Return on Invested Capital
-51.10%
N/A
Free Cash Flow
-$14.86M
+36.9%
Operating Cash Flow
-$14.81M
+36.7%